Amicus Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director Craig A. Wheeler reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
NASDAQ
Director Margaret G. McGlynn reports the disposal of all equity holdings following the completed acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
NASDAQ
Director Burke W. Whitman reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
NASDAQ
Director Glenn Sblendorio reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
NASDAQ
Director Eiry Roberts reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.
NASDAQ
Director Lynn Dorsey Bleil reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.
NASDAQ
Director Michael Kelly reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical.
NASDAQ
Director Michael Raab reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.
NASDAQ
Amicus Therapeutics Chief Accounting Officer Samantha Prout reports the disposal of all equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.
NASDAQ
Chief Development Officer Jeff Castelli reports the disposal of equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
NASDAQ
Chief People Officer David Michael Clark reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
NASDAQ
Amicus Therapeutics Chief Legal Officer Ellen Rosenberg reports the disposal of all equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.
NASDAQ
Amicus Therapeutics CFO Simon N.R. Harford reports the disposal of all equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.
NASDAQ
Amicus Therapeutics CEO Bradley L. Campbell reports the disposal of all equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.
NASDAQ
Amicus Therapeutics President and CEO, Bradley L. Campbell, sold 22,500 shares of common stock for approximately $14.35 per share under a pre-arranged 10b5-1 trading plan.
NASDAQ
Amicus Therapeutics President and CEO, Bradley L. Campbell, exercised stock options and subsequently sold 75,000 shares of common stock under a pre-arranged trading plan.
NASDAQ
Amicus Therapeutics' Chief Legal Officer, Ellen Rosenberg, reported the disposition of common stock shares in routine transactions.
NASDAQ
Amicus Therapeutics' Chief Development Officer, Jeff Castelli, reported the disposition of 29,007 common shares at $14.27 per share to cover tax liabilities.
NASDAQ
Amicus Therapeutics' Chief Accounting Officer, Samantha Prout, reported the sale of common stock totaling 15,683 shares for tax purposes.
NASDAQ
Amicus Therapeutics' Chief People Officer, David Michael Clark, reported the sale of 23,879 shares of common stock at $14.27 per share to cover tax liabilities.
NASDAQ
Amicus Therapeutics' President and CEO, Bradley L. Campbell, reported the disposition of 108,602 common shares at $14.25 per share, retaining over 1 million shares.
NASDAQ
Amicus Therapeutics' CFO, Simon N.R. Harford, reported the disposition of 71,303 common shares at $14.25 each, executed under a Rule 10b5-1 plan.
NASDAQ
Amicus Therapeutics' Chief People Officer, David Michael Clark, sold 25,642 shares of common stock for $14.1713 per share, pursuant to a pre-arranged 10b5-1 trading plan.
NASDAQ
Amicus Therapeutics President and CEO, Bradley L. Campbell, exercised stock options and subsequently sold a portion of his shares under a pre-arranged trading plan.
NASDAQ
Amicus Therapeutics' Chief People Officer, David Michael Clark, sold 25,643 shares of common stock for $11 per share, executed under a pre-arranged 10b5-1 trading plan.
NASDAQ
Amicus Therapeutics CEO Bradley L. Campbell executed a pre-planned sale of 14,587 common shares after exercising stock options.
NASDAQ
Amicus Therapeutics' Chief Accounting Officer, Samantha Prout, was granted 32,193 Restricted Stock Units.
NASDAQ
Amicus Therapeutics' Chief Development Officer, Jeff Castelli, exercised stock options and subsequently sold a portion of his common stock holdings.
NASDAQ
Amicus Therapeutics' Chief People Officer, David Michael Clark, sold 25,643 shares of common stock for a weighted average price of $10.0976 per share.
NASDAQ
Amicus Therapeutics CEO Bradley L. Campbell exercised stock options and sold common stock under a pre-arranged 10b5-1 trading plan.